<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047757</url>
  </required_header>
  <id_info>
    <org_study_id>Leg4LifeDIG</org_study_id>
    <nct_id>NCT05047757</nct_id>
  </id_info>
  <brief_title>Amino Acid Bioavilability of Fava Beans</brief_title>
  <acronym>Leg4Life</acronym>
  <official_title>Fava Bean Protein and Amino Acid Bioavailability in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Recherche Agronomique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AgroParisTech</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut National de la Recherche Agronomique</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the project is to determine the ileal amino acid digestibility of Favabean in&#xD;
      healthy subjects equipped with naso-ileal tube. For this purpose, Favabean will be&#xD;
      intrinsically labelled with 15N using 15N fertilizer. This procedure will be realized in&#xD;
      Finland and the labelled material will be sent to the Unit PNCA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective is to determine the nutritional quality of protein from favabean in healthy&#xD;
      humans, especially in terms of amino acid digestibility. Ileal digestibility is determined in&#xD;
      ileal digesta collected postprandially with a naso-ileal tube. The favabeans are&#xD;
      intrinsically labelled in 15N in order to track dietary nitrogen and amino acids in the&#xD;
      samples.&#xD;
&#xD;
      Ethical and regulatory aspects:&#xD;
&#xD;
      The protocole was submitted to the Ethical Committee for approval and to the French Agency of&#xD;
      Drugs and Health for administrative authorization. The personal data management will be in&#xD;
      accordance with the regulation on personal data protection ( &quot; regulation n° 2018-493 du 20&#xD;
      juin 2018&quot;).&#xD;
&#xD;
      Meal:&#xD;
&#xD;
      The meal will consist in 250 g of cooked and peeled favabean, to provide 20 g protein.&#xD;
      Sensory tests will be realized to optimize the organoleptic properties of the meal. 15N&#xD;
      labelled bean will be boiled in water with salt. On the morning of the experiment, the&#xD;
      portion of fava bean will be warmed up.&#xD;
&#xD;
      Volunteers:&#xD;
&#xD;
      Eight subjects will be included in the study. The investigators plan to recruit around 16&#xD;
      volunteers to accommodate for the usual 50% dropouts.&#xD;
&#xD;
      One week before the experiment, the volunteers will follow a standard diet adapted to their&#xD;
      body weight to control their protein intake (1.3 g protein/kg body weight). They will be ask&#xD;
      to consume one to 3 portions of favabean in the week.&#xD;
&#xD;
      The volunteers will arrive at the Human Nutrition Research Centre of Avicenne Hospital on the&#xD;
      morning before the day of the experiment. They will be equipped with a double lumen&#xD;
      intestinal tube that will be allowed to progress through the intestinal tract for 24h. One of&#xD;
      the lumen is radio opaque and serves to perfuse a non-absorbable maker in the intestine (slow&#xD;
      marker method). The other lumen is dedicated to the continuous aspiration of the effluents,&#xD;
      15 cm below the perfusion site. The measurement of the non-absorbable marker in the effluents&#xD;
      allows the determination of the effluent flow rate.&#xD;
&#xD;
      On the day of the experiment, the position of the tube will be checked by radiography to&#xD;
      verify its location at the terminal ileum. A catheter will be inserted in the forearm vein&#xD;
      for blood sampling. The perfusion of the non-absorbable marker, PEG-4000 (20g/l), will start&#xD;
      at a flow rate of 1ml/min. The intestinal flow and the basal ileal sample will be collected&#xD;
      during 30 min. Basal plasma sample will be sampled.&#xD;
&#xD;
      Then, at t=0, the volunteers will drink the test-meal. Until t=8h, intestinal content will be&#xD;
      continuously collected by aspiration and pooled every 30 minutes. Blood will be sampled every&#xD;
      30 minutes during 4h and hourly thereafter. The urine will be collected every 2 h for 8 h.&#xD;
&#xD;
      Subjects will collect stools samples at home during the 48 h after the meal. Stools will be&#xD;
      sent to Finland.&#xD;
&#xD;
      Measurements:&#xD;
&#xD;
      In the digesta:&#xD;
&#xD;
      PEG-4000 by turbidimetric method, total N and 15N enrichment by EA-IRMS, amino acid&#xD;
      concentrations by UPLC (after acid hydrolysis HCl 6N at 110°C for 24h), 15N amino acid&#xD;
      enrichment by GC-c-IRMS (after purification on cation exchange resin and derivatization).&#xD;
&#xD;
      In the plasma:&#xD;
&#xD;
      Glucose, urea (colorimetric methods), insulin (ELISA), amino acid concentrations (UPLC), 15N&#xD;
      enrichment in plasma protein, urea and free amino acids (EA-IRMS, after purification on&#xD;
      cation exchange resin and derivatization).&#xD;
&#xD;
      In the urine:&#xD;
&#xD;
      Urea (colorimetric method) and 15N urea (EA-IRMS, after purification on cation exchange resin&#xD;
      and derivatization).&#xD;
&#xD;
      In the stools:&#xD;
&#xD;
      Micriobial DNA.&#xD;
&#xD;
      Outcomes:&#xD;
&#xD;
      Real ileal digestibility of protein and amino acids (digestive losses), Postprandial&#xD;
      deamination (metabolic losses), Net Postprandial Protein Utilization, Microbiota composition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ileal digestibility of protein and amino acids</measure>
    <time_frame>-30 minutes to 8 hours after the test meal</time_frame>
    <description>The measurement of nitrogen (mmol) and 15N enrichment (atom %) in ileal samples allow to determine the amount of dietary nitrogen in the lumen. The measurement of amino acid concentration (mmol) and their individual 15N enrichment (atom %) allow the determination of dietary amino acids remaining in the lumen.&#xD;
Dietary amino acids and dietary nitrogen that are recovered in the ileal samples are then considered as non absorbed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Net Postprandial Protein Utilization (NPPU)</measure>
    <time_frame>0 to 8 hours after the test meal</time_frame>
    <description>The measurement of urea (mmol) and 15N enrichment of urea (atom %) allow to determine the amount of dietary N that was transferred to urea, thus accounting for metabolic losses. Metabolic losses of dietary N, together with digestive losses of dietary N, are not retained in the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gut microbiota in response to the ingestion of 15N fava bean</measure>
    <time_frame>0 to 2 days after the test meal</time_frame>
    <description>Microbial DNA sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nitrogen metabolites in blood in response to the ingestion of 15N fava bean</measure>
    <time_frame>0 to 8 hours after the test meal</time_frame>
    <description>urea and amino acids (mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose in blood in response to the ingestion of 15N fava bean</measure>
    <time_frame>0 to 8 hours after the test meal</time_frame>
    <description>plasma glucose (mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma insulin in blood in response to the ingestion of 15N fava bean</measure>
    <time_frame>0 to 8 hours after the test meal</time_frame>
    <description>plasma insulin (pmol/l)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Ileal Digestibility of Amino Acids</condition>
  <arm_group>
    <arm_group_label>Fava bean</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention consists in a test meal containing 250 g of cooked and peeled favabean, to provide 20 g protein. Fava bean are intrinsically labelled with 15N.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Test meal with 15N labeled favabean</intervention_name>
    <description>Ingestion of a 15N labeled test meal. Subjects are equipped with a nasoileal tube. 15N is followed in biological fluids (plasma, effluents, urines).</description>
    <arm_group_label>Fava bean</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18&lt;BMI&lt;30&#xD;
&#xD;
          -  Good health (WHO=0)&#xD;
&#xD;
          -  For woman: use of birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergy against legumes&#xD;
&#xD;
          -  allergy against latex&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  Positive serology for AgHBS, AcHbc, HCV, HIV&#xD;
&#xD;
          -  Positive PCR test for SARS-Cov2&#xD;
&#xD;
          -  Anemia&#xD;
&#xD;
          -  Excessive alcohool consumption&#xD;
&#xD;
          -  Hypertension, diabetes, digestive, hepatic or renal diseases, cardiac disease&#xD;
&#xD;
          -  Exercice&gt;7h/week&#xD;
&#xD;
          -  Blood donation within 3 months before the study&#xD;
&#xD;
          -  Participation to another clinical study within 3 months before the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire Gaudichon, PhD, Prof</last_name>
    <role>Study Director</role>
    <affiliation>AgroParisTech</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Benamouzig, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire gaudichon, PhD, Prof</last_name>
    <phone>33144081829</phone>
    <email>claire.gaudichon@agroparistech.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gheorghe Airinei, MD</last_name>
    <email>gheorghe.airinei@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de Recherche sur Volontaires (CRV), Hospital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <state>Ile-de-France</state>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Benamouzig</last_name>
      <phone>+33 1 48 95 53 34</phone>
      <email>robert.benamouzig@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Robert Benamouzig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut National de la Recherche Agronomique</investigator_affiliation>
    <investigator_full_name>Robert Benamouzig</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>digestibility</keyword>
  <keyword>healthy humans</keyword>
  <keyword>nasoileal tubes</keyword>
  <keyword>stable isotopes</keyword>
  <keyword>legumes</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

